JP2023531493A - Ｉｌ－１０突然変異タンパク質及びその融合タンパク質 - Google Patents

Ｉｌ－１０突然変異タンパク質及びその融合タンパク質 Download PDF

Info

Publication number
JP2023531493A
JP2023531493A JP2022578995A JP2022578995A JP2023531493A JP 2023531493 A JP2023531493 A JP 2023531493A JP 2022578995 A JP2022578995 A JP 2022578995A JP 2022578995 A JP2022578995 A JP 2022578995A JP 2023531493 A JP2023531493 A JP 2023531493A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531493A5 (https=
Inventor
スー，ハイリン
フォルツ，イアン
モック，マリッサ
ルナ，ビクター・ミッチ
ジャン，ミン
ワンバーグ，シャロン
カンデア・タピア，ガムゼ・オズレム
ライリー，ティモシー・ピー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023531493A publication Critical patent/JP2023531493A/ja
Publication of JP2023531493A5 publication Critical patent/JP2023531493A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/005—Mechanical details of housing or structure aiming to accommodate the power transfer means, e.g. mechanical integration of coils, antennas or transducers into emitting or receiving devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022578995A 2020-06-26 2021-06-25 Ｉｌ－１０突然変異タンパク質及びその融合タンパク質 Pending JP2023531493A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063045041P 2020-06-26 2020-06-26
US63/045,041 2020-06-26
US202063199218P 2020-12-14 2020-12-14
US63/199,218 2020-12-14
PCT/US2021/039191 WO2021263167A2 (en) 2020-06-26 2021-06-25 Il-10 muteins and fusion proteins thereof

Publications (2)

Publication Number Publication Date
JP2023531493A true JP2023531493A (ja) 2023-07-24
JP2023531493A5 JP2023531493A5 (https=) 2024-06-19

Family

ID=77071744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578995A Pending JP2023531493A (ja) 2020-06-26 2021-06-25 Ｉｌ－１０突然変異タンパク質及びその融合タンパク質

Country Status (17)

Country Link
US (1) US20230265145A1 (https=)
EP (1) EP4172184A2 (https=)
JP (1) JP2023531493A (https=)
KR (1) KR20230027300A (https=)
CN (1) CN116209459A (https=)
AU (1) AU2021296917A1 (https=)
CA (1) CA3187576A1 (https=)
CL (3) CL2022003755A1 (https=)
CO (1) CO2023000431A2 (https=)
CR (1) CR20230025A (https=)
IL (1) IL299149A (https=)
JO (1) JOP20220348A1 (https=)
MX (1) MX2022016548A (https=)
PE (1) PE20231082A1 (https=)
TW (1) TW202216743A (https=)
UY (1) UY39298A (https=)
WO (1) WO2021263167A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118240058A (zh) * 2022-12-24 2024-06-25 广东菲鹏制药股份有限公司 Il10突变体、融合蛋白和药物
CN116425857B (zh) * 2023-06-09 2023-08-18 苏州依科赛生物科技股份有限公司 一种无糖基化修饰的il-15及制备方法
CN117143235B (zh) * 2023-10-26 2024-02-09 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及应用
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DE19851675A1 (de) * 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
AU2003280315A1 (en) * 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2013311606B2 (en) 2012-09-07 2017-10-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof
PL3369435T3 (pl) * 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
WO2017152102A2 (en) * 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 18, JPN6025023632, 2000, pages 13552 - 13557, ISSN: 0005770337 *

Also Published As

Publication number Publication date
WO2021263167A3 (en) 2022-04-21
KR20230027300A (ko) 2023-02-27
CL2024003619A1 (es) 2025-03-14
UY39298A (es) 2022-01-31
CR20230025A (es) 2023-10-05
CL2024003618A1 (es) 2025-03-14
MX2022016548A (es) 2023-03-14
CA3187576A1 (en) 2021-12-30
CN116209459A (zh) 2023-06-02
CL2022003755A1 (es) 2023-07-21
PE20231082A1 (es) 2023-07-17
AU2021296917A1 (en) 2023-02-02
IL299149A (en) 2023-02-01
JOP20220348A1 (ar) 2022-12-22
US20230265145A1 (en) 2023-08-24
TW202216743A (zh) 2022-05-01
EP4172184A2 (en) 2023-05-03
WO2021263167A2 (en) 2021-12-30
CO2023000431A2 (es) 2023-03-27

Similar Documents

Publication Publication Date Title
JP6621778B2 (ja) ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
JP7263007B2 (ja) 抗ｔｌ１ａ／抗ｔｎｆ－アルファ二重特異性抗原結合タンパク質及びその使用
JP7603205B2 (ja) 抗体分子
JP6163158B2 (ja) Ｃｄ４０ｌに拮抗する抗体ポリペプチド
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
JP6976322B2 (ja) 新規抗ｃｔｌａ４抗体
US20170304437A1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
TW202132347A (zh) 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
JP2023531493A (ja) Ｉｌ－１０突然変異タンパク質及びその融合タンパク質
TW202033556A (zh) 拮抗性cd40單株抗體及其用途
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
CN105324127B (zh) 对baff和b7rp1具有特异性的蛋白和其用途
TW201039847A (en) Antibodies against human tweak and uses thereof
US20240279332A1 (en) Treatment of Cardiovascular Disease with TREM-1 Antigen Binding Proteins
TW202322846A (zh) 新穎的il27受體促效劑及其使用方法
JP7756686B2 (ja) ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
KR20250050855A (ko) Igf1r 항체
CN117751142A (zh) 用trem-1抗原结合蛋白治疗心血管疾病
TW202144425A (zh) 特異性抗原結合分子，其製備方法及醫藥用途
EA051986B1 (ru) Антигенсвязывающий белок и слитый белок, его содержащий
JP6529602B2 (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
AU2021331087A1 (en) Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
BR122025021892A2 (pt) Células hospedeiras

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417